MD20160102A2 - Cromen şi 1,1a,2,7b-tetrahidrociclopropa[c]cromen piridopirazindione ca modulatori ai gama-secretazei - Google Patents
Cromen şi 1,1a,2,7b-tetrahidrociclopropa[c]cromen piridopirazindione ca modulatori ai gama-secretazei Download PDFInfo
- Publication number
- MD20160102A2 MD20160102A2 MDA20160102A MD20160102A MD20160102A2 MD 20160102 A2 MD20160102 A2 MD 20160102A2 MD A20160102 A MDA20160102 A MD A20160102A MD 20160102 A MD20160102 A MD 20160102A MD 20160102 A2 MD20160102 A2 MD 20160102A2
- Authority
- MD
- Moldova
- Prior art keywords
- chromene
- pyridopyrazinediones
- tetrahydrocyclopropa
- gamma
- secretase modulators
- Prior art date
Links
- VHNYOQKVZQVBLC-RTCGXNAVSA-N (4r,7e,9as)-7-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]-4-(3,4,5-trifluorophenyl)-1,3,4,8,9,9a-hexahydropyrido[2,1-c][1,4]oxazin-6-one Chemical compound C1([C@@H]2COC[C@@H]3CC\C(C(N32)=O)=C/C=2C=C(C(=CC=2)N2C=C(C)N=C2)OC)=CC(F)=C(F)C(F)=C1 VHNYOQKVZQVBLC-RTCGXNAVSA-N 0.000 title abstract 2
- 229940124648 γ-Secretase Modulator Drugs 0.000 title abstract 2
- SAHJDJADXDVCIH-UHFFFAOYSA-N N=1C(C(N=C2C1C=CC=N2)=O)=O.C2C1COC=3C=CC=CC3C12 Chemical class N=1C(C(N=C2C1C=CC=N2)=O)=O.C2C1COC=3C=CC=CC3C12 SAHJDJADXDVCIH-UHFFFAOYSA-N 0.000 title 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 206010044688 Trisomy 21 Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Sunt dezvăluiţi compuşi cu Formula I şi sărurile farmaceutic acceptabile ale acestoraunde X, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6, R7, y şi z sunt aşa cum sunt definiţi în descriere. Sunt de asemenea dezvăluite compoziţii farmaceutice, metode de tratament, metode de sinteză şi produşi intermediari. Aceşti compuşi au proprietăţi de modulatori ai γ-secretazei şi pot fi utili în tratamentul maladiilor neurodegenerative şi/sau neurologice, aşa ca boala Alzheimer şi sindromul Down.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461973436P | 2014-04-01 | 2014-04-01 | |
| PCT/IB2015/051988 WO2015150957A1 (en) | 2014-04-01 | 2015-03-18 | Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MD20160102A2 true MD20160102A2 (ro) | 2017-04-30 |
Family
ID=52815058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20160102A MD20160102A2 (ro) | 2014-04-01 | 2015-03-18 | Cromen şi 1,1a,2,7b-tetrahidrociclopropa[c]cromen piridopirazindione ca modulatori ai gama-secretazei |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20150274721A1 (ro) |
| EP (1) | EP3126361B1 (ro) |
| JP (1) | JP6643247B2 (ro) |
| KR (1) | KR101886945B1 (ro) |
| CN (1) | CN106211770B (ro) |
| AP (1) | AP2016009465A0 (ro) |
| AR (1) | AR099874A1 (ro) |
| AU (1) | AU2015242330B2 (ro) |
| BR (1) | BR112016022519A8 (ro) |
| CA (1) | CA2944308A1 (ro) |
| CL (1) | CL2016002422A1 (ro) |
| CR (1) | CR20160454A (ro) |
| CU (1) | CU20160140A7 (ro) |
| DK (1) | DK3126361T3 (ro) |
| DO (1) | DOP2016000266A (ro) |
| EA (1) | EA031419B1 (ro) |
| EC (1) | ECSP16078289A (ro) |
| ES (1) | ES2759277T3 (ro) |
| IL (1) | IL248154B (ro) |
| MD (1) | MD20160102A2 (ro) |
| MX (1) | MX369074B (ro) |
| NI (1) | NI201600149A (ro) |
| PE (1) | PE20161364A1 (ro) |
| PH (1) | PH12016501864A1 (ro) |
| SG (1) | SG11201607465UA (ro) |
| TW (1) | TWI568733B (ro) |
| UY (1) | UY36054A (ro) |
| WO (1) | WO2015150957A1 (ro) |
| ZA (1) | ZA201606252B (ro) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| MX368391B (es) * | 2015-02-03 | 2019-09-30 | Pfizer | Ciclopropabenzofuranil-piridopirazindionas novedosas. |
| CN106580997B (zh) * | 2016-12-09 | 2018-01-19 | 张田 | 一种治疗先兆流产的药物组合物 |
| AU2017376109A1 (en) | 2016-12-16 | 2019-07-11 | Pipeline Therapeutics, Inc. | Methods of treating cochlear synaptopathy |
| WO2020053654A1 (en) * | 2018-09-12 | 2020-03-19 | Novartis Ag | Antiviral pyridopyrazinedione compounds |
| CN110907542A (zh) * | 2018-09-17 | 2020-03-24 | 复旦大学 | 一种液质联用检测唾液中司来吉兰及其代谢物的方法 |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| WO2020179859A1 (ja) | 2019-03-06 | 2020-09-10 | 第一三共株式会社 | ピロロピラゾール誘導体 |
| AR120045A1 (es) | 2019-09-26 | 2022-01-26 | Novartis Ag | Compuestos antivirales de pirazolopiridinona |
| WO2024084363A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Use of patatin-like phospholipase domain-containing protein 3 compounds |
| WO2024084360A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0683234B2 (en) | 1993-01-25 | 2007-06-06 | Takeda Chemical Industries, Ltd. | Antibody against beta-amyloid or their derivative and use thereof |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| DK0994728T3 (da) | 1997-04-09 | 2008-12-01 | Intellect Neurosciences Inc | Rekombinante antistoffer, som er specifikke for beta-amyloide ender, DNA, der koder derfor, samt fremgangsmåder til anvendelse heraf |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| EP1257584B2 (en) | 2000-02-24 | 2013-03-06 | Washington University St. Louis | Humanized antibodies that sequester amyloid beta peptide |
| DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
| NZ544691A (en) | 2000-11-03 | 2007-12-21 | Proteotech Inc | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants |
| CA2451998A1 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Anti-a.beta. antibodies |
| US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| MXPA04008364A (es) * | 2002-02-28 | 2005-07-26 | Sanofi Aventis | Derivados de 2-piridinil y 2-pirimidinil-6, 7, 8, 9-tetrahidropirmido [1,2-a] pirimidin-4-ona substituidos por heteroarilo. |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| KR20050071564A (ko) | 2002-10-09 | 2005-07-07 | 리나트 뉴로사이언스 코퍼레이션 | 아밀로이드 베타 펩티드에 대한 항체를 사용하여알츠하이머병을 치료하는 방법 및 그의 조성물 |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| JP2006527756A (ja) | 2003-06-19 | 2006-12-07 | ファイザー・プロダクツ・インク | Ｎｋ１拮抗薬 |
| EP1666061A1 (en) | 2003-09-09 | 2006-06-07 | Takeda Pharmaceutical Company Limited | Use of antibody |
| GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| EP1720847A1 (en) | 2004-02-02 | 2006-11-15 | Pfizer Products Incorporated | Histamine-3 receptor modulators |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| EA016357B1 (ru) | 2004-07-30 | 2012-04-30 | Ринат Ньюросайенс Корп. | Антитела, направленные против бета-амилоидного пептида, и способы их применения |
| GB0423356D0 (en) | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
| US20090074775A1 (en) | 2004-12-22 | 2009-03-19 | David Michael Holtzman | Use Of Anti-AB Antibody To Treat Traumatic Brain Injury |
| UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
| BRPI0609225A2 (pt) | 2005-05-12 | 2010-03-09 | Pfizer | formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas |
| WO2006126083A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors |
| WO2006126081A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors |
| CA2608672A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
| ES2354569T3 (es) | 2005-06-22 | 2011-03-16 | Pfizer Products Inc. | Antagonistas del receptor de histamina-3. |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| CA2624625A1 (en) | 2005-11-04 | 2007-05-10 | Pfizer Limited | Tetrahydronaphthyridine derivative |
| WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
| WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| JP2009539762A (ja) | 2006-03-13 | 2009-11-19 | ファイザー・プロダクツ・インク | Ｈ３受容体のテトラリン拮抗薬 |
| ES2366239T3 (es) | 2006-04-21 | 2011-10-18 | Pfizer Products Inc. | Piridin[3,4-b]pirazinonas. |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| WO2008090429A1 (en) | 2007-01-22 | 2008-07-31 | Pfizer Products Inc. | Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof |
| US8436016B2 (en) * | 2008-10-23 | 2013-05-07 | Scott D. Kuduk | Fused heterocyclic M1 receptor positive allosteric modulators |
| ES2602794T3 (es) | 2011-03-31 | 2017-02-22 | Pfizer Inc | Piridinonas bicíclicas novedosas |
| NZ702611A (en) * | 2012-05-16 | 2016-10-28 | Cellzome Ltd | Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer’s disease |
| UA110688C2 (uk) * | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| HK1212346A1 (en) * | 2013-01-17 | 2016-06-10 | Janssen Pharmaceutica Nv | Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators |
| JP6425717B2 (ja) * | 2013-10-04 | 2018-11-21 | ファイザー・インク | ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン |
-
2015
- 2015-03-18 DK DK15714951.9T patent/DK3126361T3/da active
- 2015-03-18 CA CA2944308A patent/CA2944308A1/en not_active Withdrawn
- 2015-03-18 KR KR1020167030135A patent/KR101886945B1/ko not_active Expired - Fee Related
- 2015-03-18 SG SG11201607465UA patent/SG11201607465UA/en unknown
- 2015-03-18 EP EP15714951.9A patent/EP3126361B1/en active Active
- 2015-03-18 EA EA201600619A patent/EA031419B1/ru not_active IP Right Cessation
- 2015-03-18 AP AP2016009465A patent/AP2016009465A0/en unknown
- 2015-03-18 CR CR20160454A patent/CR20160454A/es unknown
- 2015-03-18 ES ES15714951T patent/ES2759277T3/es active Active
- 2015-03-18 WO PCT/IB2015/051988 patent/WO2015150957A1/en not_active Ceased
- 2015-03-18 BR BR112016022519A patent/BR112016022519A8/pt not_active IP Right Cessation
- 2015-03-18 MD MDA20160102A patent/MD20160102A2/ro not_active Application Discontinuation
- 2015-03-18 PE PE2016001895A patent/PE20161364A1/es not_active Application Discontinuation
- 2015-03-18 CN CN201580018466.7A patent/CN106211770B/zh not_active Expired - Fee Related
- 2015-03-18 MX MX2016012904A patent/MX369074B/es active IP Right Grant
- 2015-03-18 JP JP2016559879A patent/JP6643247B2/ja not_active Expired - Fee Related
- 2015-03-18 AU AU2015242330A patent/AU2015242330B2/en not_active Ceased
- 2015-03-27 UY UY0001036054A patent/UY36054A/es not_active Application Discontinuation
- 2015-03-27 US US14/670,746 patent/US20150274721A1/en not_active Abandoned
- 2015-03-27 AR ARP150100922A patent/AR099874A1/es unknown
- 2015-03-31 TW TW104110551A patent/TWI568733B/zh not_active IP Right Cessation
-
2016
- 2016-09-09 ZA ZA2016/06252A patent/ZA201606252B/en unknown
- 2016-09-22 PH PH12016501864A patent/PH12016501864A1/en unknown
- 2016-09-22 CU CUP2016000140A patent/CU20160140A7/es unknown
- 2016-09-27 CL CL2016002422A patent/CL2016002422A1/es unknown
- 2016-09-29 IL IL248154A patent/IL248154B/en active IP Right Grant
- 2016-09-29 DO DO2016000266A patent/DOP2016000266A/es unknown
- 2016-09-29 NI NI201600149A patent/NI201600149A/es unknown
- 2016-09-30 EC ECIEPI201678289A patent/ECSP16078289A/es unknown
-
2017
- 2017-02-24 US US15/441,882 patent/US20170166566A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD20160102A2 (ro) | Cromen şi 1,1a,2,7b-tetrahidrociclopropa[c]cromen piridopirazindione ca modulatori ai gama-secretazei | |
| MX2021008583A (es) | Composiciones para el tratamiento de trastornos del snc. | |
| SG10201811384TA (en) | Mnk inhibitors and methods related thereto | |
| PH12020550503A1 (en) | Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors | |
| PH12016501977A1 (en) | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | |
| EP4464317A3 (en) | Compounds and compositions and uses thereof | |
| MX2019014292A (es) | Anillos 5-5 fusionados como inhibidores c5a. | |
| MY191352A (en) | Aldosterone synthase inhibitors | |
| PH12017500595A1 (en) | Aldosterone synthase inhibitors | |
| PH12017501369A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| MX377032B (es) | Compuestos de dihidroquinolinsulfonamida de alquilo. | |
| MX2016008968A (es) | Compuestos organicos. | |
| PH12017501134A1 (en) | Fumagillol derivatives | |
| PH12019502792A1 (en) | Tetrahydropyridopyrazine modulators of gpr6 | |
| IN2013MU03838A (ro) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA9A | Abandonment or withdrawal of application (patent for invention) |